OAB and Incontinence

These 5 overactive bladder research papers were recently published in peer-reviewed academic journals.

Investigators observed a median 74% reduction in urinary incontinence episodes at 1 year for women undergoing group-based pelvic floor muscle training compared with a 70% reduction in women undergoing individual PFMT.

"Patients undergoing midurethral sling placement are ideal for postoperative virtual visits," writes Priya Padmanabhan, MD, MPH.

A new trial is exploring whether CLARIX CORD 1K, a cryopreserved umbilical cord allograft, can contribute to a faster return of erectile function and urinary continence after robot-assisted radical prostatectomy.

Investigators reported that the treatment-emergent adverse event results showed combination tamsulosin and mirabegron was well-tolerated and had a favorable safety profile.

The technique also led to better preservation of anatomical structures around the urethra and achieved a low rate of positive surgical margins.

Bilal Chughtai, MD, and Ahra Cho discuss a recent study evaluating the efficacy of dried cranberry powder in women with overactive bladder.

The ELITE study is exploring the InterStim Micro neurostimulator in patients with urinary urge incontinence, urinary frequency, non-obstructive urinary retention, and fecal incontinence.

R. Corey O'Connor, MD, discusses findings from a recent study published in Neurourology and Urodynamics.

Lunan Ji, MD, discusses a recent paper published in Urology that evaluated the quality of patient education materials on YouTube related to overactive bladder.

“Although IPSS may not be familiar to gynecologists and urogynecologists, this minimally invasive self-reported questionnaire is useful in counseling preoperative pelvic organ prolapse patients with OAB symptoms," researchers write.

“The present study clearly shows that test duration and reprogramming during the test phase increases the number of patients that benefit in the long term from sacral neuromodulation,” researchers wrote.

Outcomes for patients using telemedicine were equal, and patients were as satisfied as those who had office-based postoperative visits.

Smoking had a particularly strong impact on OAB risk in younger individuals.

Gopal H. Badlani, MD, discusses the recently presented long-term safety profile of the β-3 adrenoceptor agonist vibegron.

Jeffrey P. Weiss, MD, PhD, discusses how he defines nocturia, how to separate the symptom from overactive bladder, and how he conducts patient work-ups for nocturia

Data from a pivotal trial showed the eCoin Peripheral Neurostimulator led to a clinically significant improvement in urgency urinary incontinence.

Beta 3-adrenergic receptor agonist’s benefits observed at 52 weeks, investigators report.

The OASIS study is examining the RENOVA iStim implantable tibial neuromodulation system for the treatment of women with overactive bladder.

InterStim Micro treats patients with overactive bladder, fecal incontinence, and non-obstructive urinary retention by delivering sacral neuromodulation therapy.

Feasibility study results indicate the nonimplanted, intravaginal device is safe and comfortable.

Treatment with litoxetine, an investigational oral selective serotonin reuptake inhibitor, led to nearly 22% of patients becoming continent.

The reduction in urinary urgency incontinence episodes observed was “quite significant,” an investigator said.

Urologists must differentiate between bladder outlet obstruction and pure OAB in male patients, according to Osvaldo F. Padron, MD.

An investigational wireless, implantable tibial nerve stimulator is safe and provided improvement in overactive bladder symptoms over 3 years of follow-up.

Mirabegron (Myrbetriq) is effective and well tolerated in patients age 65 or older with overactive bladder, results of a randomized, placebo-controlled study show.

A recent study found that sacral neuromodulation monotherapy was efficacious as a third-line treatment.

Nocturia appears to be highly prevalent in the United States, with almost 30% of all women reporting significant nocturia, according to new data reported at the AUA annual meeting in San Francisco.

 Waking up at night to urinate is by far the most bothersome lower urinary tract symptom. 

The therapeutic efficacy of sacral neuromodulation was not affected by non-head magnetic resonance imaging scans in a recent study.